What is the recommended management for a patient with liver cirrhosis?

Management of Liver Cirrhosis

First-line management of cirrhosis with ascites consists of dietary sodium restriction to 2000 mg (88 mmol) per day combined with oral diuretics—specifically spironolactone with or without furosemide—while addressing the underlying etiology and screening for complications. 1, 2, 3

Initial Assessment and Etiology Management

When cirrhosis is diagnosed, immediately identify and treat the underlying cause:

• Alcohol-related disease: Absolute alcohol abstinence is mandatory. Patients with Child-Pugh C cirrhosis who stop drinking have approximately 75% 3-year survival, while those who continue drinking have 0% survival at 3 years 4
• Viral hepatitis, metabolic disease, or other etiologies: Initiate disease-specific treatment
• Diagnostic paracentesis: Perform in all patients with new-onset ascites or hospital admission for ascites/encephalopathy. Test for serum-ascites albumin gradient (SAAG), cell count, Gram stain, and culture 3

Ascites Management Algorithm

Grade 2 Ascites (Moderate)

Start with:

• Sodium restriction: 2000 mg (88 mmol) daily 1, 2
• Spironolactone: Begin at 100 mg once daily
• Furosemide: Add 40 mg once daily if needed
• Fluid restriction: NOT necessary unless serum sodium drops below 120-125 mmol/L 1, 2

Titration strategy: Increase diuretic doses every 3-5 days until achieving weight loss and natriuresis. Maximum doses are spironolactone 400 mg/day and furosemide 160 mg/day 1

Monitoring: Check body weight, serum creatinine, sodium, and potassium regularly. Target weight loss of 0.5 kg/day without peripheral edema, or 1 kg/day with edema 2

Grade 3 Ascites (Tense)

• Large-volume paracentesis (LVP): First-line treatment, removes fluid in minutes versus days-to-weeks with diuretics 4, 1
• Albumin replacement: Give 6-8 g of 20-25% IV albumin per liter removed when volume exceeds 5 L. Consider albumin for smaller volumes if hypotension, renal insufficiency, or electrolyte abnormalities present 3
• Follow with sodium restriction and diuretics to prevent reaccumulation 1, 2

Refractory Ascites

Defined as ascites unresponsive to maximum diuretic doses (spironolactone 400 mg + furosemide 160 mg daily) or rapid recurrence after paracentesis 1

Management options:

1. Serial therapeutic paracenteses: Frequency guided by recurrence 3
2. TIPS (transjugular intrahepatic portosystemic shunt): For well-selected patients with refractory ascites 3
3. Liver transplantation evaluation: Should be initiated 1, 2

Critical Medications to AVOID

Absolutely contraindicated in cirrhosis with ascites 2, 5:

• NSAIDs (convert diuretic-sensitive to refractory ascites, induce azotemia)
• ACE inhibitors and angiotensin receptor blockers
• Aminoglycoside antibiotics whenever possible

Surveillance and Screening

Regardless of ascites status, all cirrhosis patients require:

• Hepatocellular carcinoma surveillance: Ultrasound every 6 months, even after achieving sustained virologic response in viral hepatitis 2
• Variceal screening: Upper endoscopy to assess for esophageal varices 5
• Liver transplantation evaluation: Consider when ascites develops, as this marks decompensation with significantly reduced survival 1

Diuretic Complications Requiring Dose Reduction or Discontinuation

Stop or reduce diuretics if 1:

• Serum creatinine rises to ≥2.0 mg/dL
• Serum sodium falls below 120 mmol/L
• Serum potassium exceeds 6.0 mmol/L
• Hepatic encephalopathy develops
• Minimal weight loss with urinary sodium <78 mmol/day despite maximum doses

Important caveat: Once ascites is adequately mobilized, taper diuretics to the lowest effective dose to prevent adverse effects while maintaining minimal or no ascites 2

Diabetes Management in Decompensated Cirrhosis

Screen all patients for diabetes using fasting glucose (NOT HbA1c, which is unreliable in cirrhosis). Insulin is the only evidence-based treatment option—initiate in hospital due to hypoglycemia risk that can mimic hepatic encephalopathy. Target fasting glucose <10 mmol/L. Metformin is contraindicated (lactic acidosis risk), and most other oral agents are not recommended 6

Multidisciplinary Approach

The 2025 AGA guidance emphasizes that complex cases—particularly refractory ascites, hepatic hydrothorax, or recurrent hyponatremia—benefit from multidisciplinary management including hepatology, nutrition (dietitian referral for sodium restriction education), and early involvement of transplant teams 3